Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548340 · ClinicalTrials.gov registry record · Phase 3
VEC-162 Study in Adult Patients With Primary Insomnia
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 322
- Enrollment target
NCT00548340 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 322 participants.
The verdict
NCT00548340, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 322 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.
Interventions
- DRUG Placebo
- DRUG VEC-162 20 mg
- DRUG VEC-162 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548340
The ClinicalTrials.gov registry entry for NCT00548340 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00548340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548340 about?
NCT00548340 is a clinical study titled "VEC-162 Study in Adult Patients With Primary Insomnia". The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.
What is the current status of trial NCT00548340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 322 participants. The study started on 2007-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00548340?
The interventions under investigation include: Placebo (DRUG), VEC-162 20 mg (DRUG), VEC-162 50 mg (DRUG).
Who is sponsoring clinical trial NCT00548340?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.